The human lymphokine leukoregulin induces cell resistance to complement-mediated lysis

Zvi Fishelson*, Shimon Shlanger, Yonit Bomstein, Charles H. Evans

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Leukoregulin (LR) is a lymphokine secreted by human natural killer (NK) cells. Its effect on the susceptibility of K562 human erythroleukemic cells to lysis by antibody and complement was examined. As reported here, treatment of K562 cells with LR for 60 min at 37°C confers on them resistance to complement damage. The LR-induced state of complement resistance is transient and the cells recover within 4-6 h unless a second dose of LR is added. The protective action of LR was observed using both conventional 51Cr-release and trypan blue inclusion assays. The protein synthesis inhibitors puromycin and cycloheximide and the protein kinase inhibitors tamoxifen, polymyxin B and W-7, could each block this action of LR. Fewer membrane attack complexes were found, following complement activation, on LR-treated than control cells. These results suggest that LR increases the capacity of K562 cells to down-regulate complement activation or repair the complement damage, possibly by inducing synthesis of defense proteins and/or activation of protective protein kinases.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalImmunology Letters
Issue number1
StatePublished - Mar 1992
Externally publishedYes


FundersFunder number
Israel Cancer Research Fund
Israel Academy of Sciences and Humanities
Israel Cancer Association


    • Human
    • Leukoregulin
    • Lymphokine
    • Resistance to lysis


    Dive into the research topics of 'The human lymphokine leukoregulin induces cell resistance to complement-mediated lysis'. Together they form a unique fingerprint.

    Cite this